| For: | Kak M. Rebamipide in gastric mucosal protection and healing: An Asian perspective. World J Gastrointest Pharmacol Ther 2025; 16(1): 101753 [PMID: 40094150 DOI: 10.4292/wjgpt.v16.i1.101753] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i1/101753.htm |
| Number | Citing Articles |
| 1 |
Igor V. Maev, Alsu R. Khurmatullina, Dmitrii N. Andreev, Andrew V. Zaborovsky, Yury A. Kucheryavyy, Philipp S. Sokolov, Petr A. Beliy. Rebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review. Pharmaceuticals 2026; 19(1): 144 doi: 10.3390/ph19010144
|
| 2 |
Chenyu Zou, Yu Cao, Juxiong Liu, Xian Dong, Junlong Bi, Wenjin Guo, Shoupeng Fu. Confronting bacterial mastitis: From pathogen diversity to sustainable control in the post-antibiotic era. Animals and Zoonoses 2025; doi: 10.1016/j.azn.2025.07.004
|
| 3 |
Nagla A. El-Shitany, Nageh Ahmed El-Mahdy, Ola Mahmoud Waly, Aya Hassan El-Kadem. Rebamipide modulates the miR-29a/SIRT1/FoxO3a and NF-κB pathways in methotrexate-induced testicular damage. European Journal of Pharmacology 2025; 1005: 178063 doi: 10.1016/j.ejphar.2025.178063
|
| 4 |
Jaewon Park, Kyoung Yul Seo, Hyunmin Ahn, Yearim Shin, Ikhyun Jun, Tae-im Kim, Bum Kyu Shin, Da-Young Yoon, Soo-Min Lee. Efficacy and Safety of SA001 in Patients with Primary Sjögren’s Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmaceuticals 2026; 19(1): 189 doi: 10.3390/ph19010189
|
| 5 |
Hyejoo Lee, Na Rae Lim, Seonwoo Kim, Hyun Cho, Woo Chul Chung. Comparative Efficacy and Safety of Stillen® and Rebamipide in Patients with Acute or Chronic Gastritis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2025; 14(17): 6209 doi: 10.3390/jcm14176209
|
